Search

Your search keyword '"Lam, Carolyn"' showing total 3,404 results

Search Constraints

Start Over You searched for: Author "Lam, Carolyn" Remove constraint Author: "Lam, Carolyn"
3,404 results on '"Lam, Carolyn"'

Search Results

151. Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study

152. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

154. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study

158. Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region

161. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

164. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial

166. NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories

167. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial

168. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial

170. Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®

173. Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF

174. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

175. Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation

177. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER

178. Impact of Geographic Region on the COMMANDER-HF Trial

180. Eligibility of Asian and European registry patients for phase III trials in heart failure with reduced ejection fraction.

181. Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐O trial.

182. In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial.

183. Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with the ASIAN‐HF registry.

185. Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial.

186. Artificial intelligence‐assisted automated heart failure detection and classification from electronic health records.

187. Development and validation of a machine learning‐based approach to identify high‐risk diabetic cardiomyopathy phenotype.

188. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study

189. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction

193. Abstract 9620: External Validation of Deep Learning-Based Echocardiography Algorithms to Automate View Selection and Annotation of the Echocardiogram

194. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial

195. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial

196. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

197. Design and rationale for MAGNITUDE, a phase 3, randomized, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)

198. #853 Kidney-protective medication and risk of adverse clinical outcomes in patients with chronic kidney disease: preliminary findings from DISCOVER CKD

199. #837 Information needs and emotional impact when receiving a diagnosis of chronic kidney disease: insights from DISCOVER CKD

200. MACE in COPD: addressing cardiopulmonary risk

Catalog

Books, media, physical & digital resources